{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T05:22:17Z","timestamp":1751692937818,"version":"3.40.5"},"reference-count":35,"publisher":"S. Karger AG","issue":"9","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Introduction: Dexamethasone (DEX)-sparing strategy with 5-hydroxytryptamine-3 receptor antagonist (5HT3RA) and aprepitant (APR), as triplet antiemetic prophylaxis, is associated with poor control of delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving carboplatin (CBDCA)-based chemotherapy. This study aimed to evaluate whether using palonosetron (PALO) as a 5HT3RA provides superior control with CINV than first-generation (1st) 5HT3RA in triplet antiemetic prophylaxis with a DEX-sparing strategy. Methods: Pooled patient-level data from a nationwide, multicenter, and prospective observational study were analyzed to compare the incidence of CINV between patients administered PALO and 1st 5HT3RA in combination with 1-day DEX and APR. Results: No significant differences were observed in the incidence of CINV, pattern of CINV, or severity of nausea by type of 5HT3RA in triplet antiemetic prophylaxis with DEX-sparing strategy. In both groups, the incidence of nausea gradually increased from day 3, peaked on day 4 or 5, and then declined slowly. The visual analog scale scores in the delayed phase remained high throughout the 7-day observation period. Conclusion: Careful patient selection and symptom monitoring are needed when implementing the DEX-sparing strategy in triplet antiemetic prophylaxis for patients undergoing CBDCA-based chemotherapy. Furthermore, additional strategies may be needed to achieve better control of delayed CINV. <\/jats:p>","DOI":"10.1159\/000531318","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T21:04:16Z","timestamp":1689887056000},"page":"584-590","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy"],"prefix":"10.1159","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6183-4939","authenticated-orcid":false,"given":"Toshinobu","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3365-1"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01818-3"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2015.464"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0308"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp584"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2760-3"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12675"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0133"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06061-8"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac060"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004264641"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.10.002"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70313-9"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw220"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-2046-6"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2015.26.4.311"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-015-0786-7"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000087979"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1135899"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100278"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200005253422102"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008229721099"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S176574"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.6382"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1448-1"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.08.049"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13851"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10018-3"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515725"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30678-3"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03868-5"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.01.004"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01315"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0292"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/ocl\/article-pdf\/101\/9\/584\/3996405\/000531318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/ocl\/article-pdf\/101\/9\/584\/3996405\/000531318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:33:41Z","timestamp":1745422421000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000531318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,5]]},"published-print":{"date-parts":[[2023,9,18]]}},"URL":"https:\/\/doi.org\/10.1159\/000531318","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[2023]]}}}